Oncolytics Biotech Inc T.ONC

SCOTUS rules that antibodies cannot be monopolized

[Noteable]

May 18, 2023 - In a closely fought patent battle between PCSK9 rivals Amgen and Sanofi/Regeneron, the Supreme Court ruled unanimously on Thursday that Amgen cannot monopolize the market for any and every antibody that binds to areas of the sweet spot of PCSK9.

[This ruling could further impact the FTC's review/decision on Pfizer's proposed US$43 Billion acquisition of antibody drug conjugate (ADC) company Seagen]

[westcoast1000]

Thinking back to our discussion of anti-trust and ONCY, I could imagine a future world in which it is ruled that pela cannot be monopolized. That is, its mechanism of action in changing the TME, its ease of use, its lack of side effects, and its double stranded RNA structure could concievably so unique that its future owner must agree to license to other companies. Sort of like how owners of